MORF: Morphic Company Aggregate Debts

Symbol and logo of brand Morphic Therapeutic (MORF)

The price trend for Morphic Holding, Inc. (MORF), which specializes in GI therapy, is recorded at 0.01. The professionalism of the executives and the transparency of the data regarding the lead drug secured a lucrative deal with Eli Lilly. Future revenue relies on patent protection for unique formulas to maintain pricing power, while the absence of proprietary manufacturing plants through outsourcing ensures high operational mobility for the company.

Morphic Holding, Inc. - MORF Company Debts (period 07/04/2022 - 08/24/2024)

Analytical breakdowns and data insights for company Morphic (MORF)

- price and consensus price forecast:
Price Performance Chart Morphic Holding Corp|MORF - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Morphic Holding Inc|MORF - Total Company Value
- book capitalization data:
Accounting Value of a Share Morphic|MORF - Company Book Value|Market Cap to Net Assets Ratio morphictx.com|MORF - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Morphic Holding, Inc.|MORF - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Morphic Therapeutic|MORF - Company Aggregate Debts|Debt to Net Assets Morphic Holding Inc|MORF - Company Long-Term Debts|Short-Term Debt Volume Morphic
Fundamental valuation:MORF Morphic Holding Corp
Original product of Morphic Therapeutic

This metric captures the total volume of borrowed obligations based on daily quotes, allowing for an assessment of financial stability and the business's degree of dependence on external capital. By analyzing the debt movement chart, an investor can compare the debt load of Morphic Holding, Inc. (MORF) with the costs of developing its unique oral drug platform for combating severe inflammation.

Key competitors

Aggregate Debt Obligations Phathom (PHAT)|Company Aggregate Debts TERN (Terns Pharmaceuticals)|Ironwood Pharma - Company Aggregate Debts|Company Debts Curanex (CURX)|IMRN: Aggregate Debt Obligations|EVOK (Evoke Pharma, Inc) - Company Debts|Entero Therapeutics (ENTO) - Company Total Debt|RDHL (RedHill Biopharma Ltd) - Company Aggregate Debts|Company Aggregate Debts Palisade Bio Inc. (PALI)|Jaguar Health (JAGX) - Company Total Debt|Aggregate Debt Obligations Biora Therapeutics Inc. (BIOR)